Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberonics

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific's approximately $50 mil. stake in the vagus nerve stimulation technology manufacturer demonstrates the firm's interest in the potential of deep brain stimulation. The VNS device already is approved for drug-resistant epilepsy, and Cyberonics is developing the device to treat depression. Houston, Texas-based Cyberonics will host a dinner program outlining its depression regulatory timeline Sept. 24. Cyberonics was targeted for acquisition by Medtronic in 2000, but rejected a $26-per-share takeover offer (1"The Gray Sheet" Sept. 18, 2000, p. 5)...

You may also be interested in...



Cyberonics

Boston Scientific plans to increase its stake in the vagus nerve stimulation (VNS) technology firm from nearly 15% to up to 20% of outstanding shares, after a Dec. 10 shareholder rights plan amendment clears the way. Signaling the potential for broader ties down the road, the move follows a roughly $50 mil. Boston Scientific investment earlier this year (1"The Gray Sheet" June 16, 2003, In Brief). Cyberonics, which holds FDA approval for adjunctive, drug-resistant epilepsy treatment, simultaneously announced the agency accepted for filing its October PMA supplement submission for adjunctive, drug-resistant depression treatment Dec. 9 (2"The Gray Sheet" Nov. 10, 2003, In Brief). Cyberonics has projected potential depression sales of over $1 bil. by 2010...

Cyberonics Shares Up 14% In June, Stimulated By Pending D-04 Trial Results

The promise of a concrete regulatory timeline for Cyberonics' NeuroCybernetic Prosthesis vagus nerve stimulation therapy for depression, coupled with a $50 mil. investment by Boston Scientific, drove the firm's stock price up 13.8% in June

Medtronic Holding Pat On $480 Mil. Acquisition Offer Spurned By Cyberonics

Medtronic's stalled $480 mil. acquisition bid for Cyberonics may be the first test for President and Chief Operating Officer Arthur Collins as he prepares to assume the top executive post at Medtronic next spring.

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel